Anika Therapeutics (ANIK) Capital Expenditures (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Capital Expenditures data on file, last reported at $55000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $55000.0, down 89.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $219000.0 (down 57.8% YoY), and the FY2025 annual result was $666000.0, up 4.23% from the prior year.
• Capital Expenditures declined to $55000.0 in Q1 2026 per ANIK's latest filing, from $630000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $4.6 million in Q2 2024 and troughed at -$5.8 million in Q4 2024.
• A 5-year average of $134294.1 and a median of $630000.0 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures tumbled 2265.37% in 2022, then jumped 445.3% in 2024.
• A 5-year view of Capital Expenditures shows it stood at -$4.8 million in 2022, then jumped by 42.83% to -$2.8 million in 2023, then tumbled by 108.8% to -$5.8 million in 2024, then jumped by 110.88% to $630000.0 in 2025, then sank by 91.27% to $55000.0 in 2026.
• Business Quant data shows ANIK's Capital Expenditures at $55000.0 in Q1 2026, $630000.0 in Q4 2025, and -$4.3 million in Q3 2025.